Quality of Life vs. Survival in Modern Oncology: Dr. Konstantina Boniou Interview

Modern oncology is seeing a shift in how treatment success is measured, moving beyond traditional survival metrics to prioritize the quality of life for patients. Dr. Konstantina Boniou has highlighted that patients do not measure survival in the same way that clinicians do, suggesting a need for a more patient-centric approach to cancer care.

While clinical success is often defined by overall survival rates and the extension of life through medical intervention, the patient experience is frequently defined by the ability to maintain daily functioning and personal well-being during and after treatment.

Balancing Survival and Quality of Life

The tension between extending life and maintaining a high quality of life is a central challenge in oncology. Dr. Boniou’s perspectives emphasize that the goal of treatment should not solely be the addition of time, but the quality of the time added.

This approach is particularly relevant in the context of maintenance therapy. Maintenance immunotherapy is being utilized as a method to control disease with toxicity levels that are generally manageable, especially when compared to extended treatment regimens.

Prioritizing quality of life allows treatment plans to align more closely with the individual values and needs of the patient, ensuring that the interventions do not overshadow the lived experience of the person they are intended to help.

The Role of Maintenance Therapy

Maintenance therapy serves as a strategic bridge in cancer care, aiming to keep the disease stable while minimizing the severe side effects often associated with primary induction therapies.

By focusing on manageable toxicity, clinicians can help patients avoid the debilitating effects of over-treatment, which can either diminish the quality of the remaining survival period or lead to a decrease in the patient’s overall functional status.

This shift in strategy reflects a broader movement within the medical community to recognize that survival is a multifaceted metric. The biological extension of life is only one part of the equation; the other is the patient’s ability to engage with their life and maintain a sense of normalcy.

Clinical Implications for Patient Care

Integrating patient-reported outcomes into the decision-making process is essential for aligning treatment with quality-of-life goals. This involves a dialogue between the oncologist and the patient to determine what constitutes a successful outcome for that specific individual.

For some patients, the priority may be the maximum possible extension of life regardless of the side effects. For others, the priority may be the preservation of cognitive function, mobility, or the ability to spend time with family, even if it means choosing a less aggressive treatment path.

The objective of modern oncology is increasingly focused on this balance, recognizing that the clinical definition of survival must be expanded to include the patient’s subjective experience of their health and well-being.